Suppr超能文献

当代基因组学时代的未来转化应用:美国心脏协会的科学声明

Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.

作者信息

Fox Caroline S, Hall Jennifer L, Arnett Donna K, Ashley Euan A, Delles Christian, Engler Mary B, Freeman Mason W, Johnson Julie A, Lanfear David E, Liggett Stephen B, Lusis Aldons J, Loscalzo Joseph, MacRae Calum A, Musunuru Kiran, Newby L Kristin, O'Donnell Christopher J, Rich Stephen S, Terzic Andre

出版信息

Circulation. 2015 May 12;131(19):1715-36. doi: 10.1161/CIR.0000000000000211. Epub 2015 Apr 16.

Abstract

The field of genetics and genomics has advanced considerably with the achievement of recent milestones encompassing the identification of many loci for cardiovascular disease and variable drug responses. Despite this achievement, a gap exists in the understanding and advancement to meaningful translation that directly affects disease prevention and clinical care. The purpose of this scientific statement is to address the gap between genetic discoveries and their practical application to cardiovascular clinical care. In brief, this scientific statement assesses the current timeline for effective translation of basic discoveries to clinical advances, highlighting past successes. Current discoveries in the area of genetics and genomics are covered next, followed by future expectations, tools, and competencies for achieving the goal of improving clinical care.

摘要

随着近期诸多里程碑式成就的取得,遗传学和基因组学领域有了长足发展,其中包括确定了许多心血管疾病相关基因座以及药物反应的变异性。尽管取得了这一成就,但在理解和推进直接影响疾病预防和临床护理的有意义的转化方面仍存在差距。本科学声明的目的是弥合基因发现与其在心血管临床护理中的实际应用之间的差距。简而言之,本科学声明评估了将基础发现有效转化为临床进展的当前时间线,突出了过去的成功案例。接下来涵盖遗传学和基因组学领域的当前发现,随后是对实现改善临床护理目标的未来期望、工具和能力。

相似文献

1
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.
Circulation. 2015 May 12;131(19):1715-36. doi: 10.1161/CIR.0000000000000211. Epub 2015 Apr 16.
2
3
Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
Circ Res. 2018 Apr 27;122(9):1176-1190. doi: 10.1161/CIRCRESAHA.117.310965.
4
Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association.
Circulation. 2015 Sep 1;132(9):852-72. doi: 10.1161/CIR.0000000000000226. Epub 2015 Jul 20.
5
Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association.
Circ Cardiovasc Genet. 2016 Oct;9(5):448-467. doi: 10.1161/HCG.0000000000000031. Epub 2016 Sep 26.
7
Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association.
Circ Genom Precis Med. 2020 Aug;13(4):e000067. doi: 10.1161/HCG.0000000000000067. Epub 2020 Jul 23.
9
The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.
Circulation. 2015 Dec 1;132(22):2167-92. doi: 10.1161/CIR.0000000000000297. Epub 2015 Oct 28.

引用本文的文献

1
Panoramic on Epigenetics in Coronary Artery Disease and the Approach of Personalized Medicine.
Biomedicines. 2023 Oct 23;11(10):2864. doi: 10.3390/biomedicines11102864.
2
Mitochondrial quality control in diabetic cardiomyopathy: from molecular mechanisms to therapeutic strategies.
Int J Biol Sci. 2022 Aug 15;18(14):5276-5290. doi: 10.7150/ijbs.75402. eCollection 2022.
4
Elucidation of Epigenetic Landscape in Coronary Artery Disease: A Review on Basic Concept to Personalized Medicine.
Epigenet Insights. 2021 Jan 28;14:2516865720988567. doi: 10.1177/2516865720988567. eCollection 2021.
5
Genetic and environmental risk factors for chronic kidney disease.
Kidney Int Suppl (2011). 2017 Oct;7(2):88-106. doi: 10.1016/j.kisu.2017.07.004. Epub 2017 Sep 20.
7
Personalized medicine-a modern approach for the diagnosis and management of hypertension.
Clin Sci (Lond). 2017 Nov 6;131(22):2671-2685. doi: 10.1042/CS20160407. Print 2017 Nov 15.
8
Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena.
Eur Heart J. 2018 Dec 14;39(47):4150-4158. doi: 10.1093/eurheartj/ehx568.
9
Systems biology: An emerging strategy for discovering novel pathogenetic mechanisms that promote cardiovascular disease.
Glob Cardiol Sci Pract. 2016 Sep 30;2016(3):e201627. doi: 10.21542/gcsp.2016.27.

本文引用的文献

1
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
Oncologist. 2014 Jan;19(1):94-9. doi: 10.1634/theoncologist.2013-0077. Epub 2013 Dec 5.
2
Vitamin D-binding protein and vitamin D status of black Americans and white Americans.
N Engl J Med. 2013 Nov 21;369(21):1991-2000. doi: 10.1056/NEJMoa1306357.
3
Do pharmacogenetics have a role in the dosing of vitamin K antagonists?
N Engl J Med. 2013 Dec 12;369(24):2345-6. doi: 10.1056/NEJMe1313682. Epub 2013 Nov 19.
4
A randomized trial of genotype-guided dosing of warfarin.
N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.
5
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19.
6
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
N Engl J Med. 2013 Dec 12;369(24):2304-12. doi: 10.1056/NEJMoa1311388. Epub 2013 Nov 19.
8
APOL1 risk variants, race, and progression of chronic kidney disease.
N Engl J Med. 2013 Dec 5;369(23):2183-96. doi: 10.1056/NEJMoa1310345. Epub 2013 Nov 9.
9
Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.
Int J Cardiol. 2013 Oct 9;168(4):3736-40. doi: 10.1016/j.ijcard.2013.06.014. Epub 2013 Jul 11.
10
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验